Aloka Chakravarty

Aloka Chakravarty

Auto-generated profile, based on publicly available information

Aloka Chakravarty

Office of the Commissioner U.S. Food and Drug Administration Silver Spring Maryland USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2022 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
EGElizabeth M Garry
Elizabeth M Garry
AWAndrew R. Weckstein
Andrew R. Weckstein
KQKenneth Quinto
Kenneth Quinto
MBMarie C. Bradley
Marie C. Bradley
TLTamar Lasky
Tamar Lasky
NGNicolle M. Gatto
Nicolle M. Gatto

26 May 2021 in Biomarkers in Medicine
Verified
Journal Article
Open access
SHSuzanne Hendrix
Suzanne Hendrix
RMRobin Mogg
Robin Mogg
SWSue Jane Wang
Sue Jane Wang
ACAloka Chakravarty
Aloka Chakravarty
KRKlaus Romero
Klaus Romero
LMLisa M McShane
Lisa M McShane
Qualification of a biomarker for use in a medical product development program requires a statistical strategy that aligns available evidence with the proposed context of use (COU), identifies any d...

26 September 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SVSarah E. Vititoe
Sarah E. Vititoe
IEImaani J. Easthausen
Imaani J. Easthausen
TLTamar Lasky
Tamar Lasky
ACAloka Chakravarty
Aloka Chakravarty
MBMarie C. Bradley
Marie C. Bradley
EGElizabeth M Garry
Elizabeth M Garry
Objective: To describe differences by race and ethnicity in treatment patterns among hospitalized COVID-19 patients in the US from March-August 2020.Methods: Among patients in de-identified Optum electronic health record data hospitalized with COVID-19 (March-August 2020), we estimated odds ratios of receiving COVID-19 treatments of interest (azithromycin, dexamethasone, hydroxychloroquine, remdesivir, and other steroids) at hospital admission, by race and ethnicity, after adjusting for key covariates of interest.Results: After adjusting for key covariates, Black/African American patients were less likely to receive dexamethasone (adj. OR [95% CI]: 0.83 [0.71, 0.96]) and more likely to receive other steroids corticosteroids (adj. OR [95% CI]: 2.13 [1.90, 2.39]), relative to White patients. Hispanic/Latino patients were less likely to receive dexamethasone than Not Hispanic/Latino patients (adj. OR [95% CI]: 0.69 [0.58, 0.82]).Conclusions: Our findings suggest that COVID-19 treatments patients received in Optum varied by race and ethnicity after adjustment for other possible explanatory factors. In the face of rapidly evolving treatment landscapes, policies are needed to ensure equitable access to novel and repurposed therapeutics to avoid disparities in care by race and ethnicity.

10 February 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CRCarla V Rodriguez-Watson
Carla V Rodriguez-Watson
NSNatalie E Sheils
Natalie E Sheils
ALAnthony M Louder
Anthony M Louder
EEElizabeth H Eldridge
Elizabeth H Eldridge
NLNancy D Lin
Nancy D Lin
JAJeff Allen
Jeff Allen
Background: As diagnostic tests for COVID-19 were broadly deployed under Emergency Use Authorization, there emerged a need to understand the real-world utilization and performance of serological testing across the United States. Methods: Six health systems contributed electronic health records and/or claims data, jointly developed a master protocol, and used it to execute the analysis in parallel. We used descriptive statistics to examine demographic, clinical, and geographic characteristics of serology testing among patients with RNA positive for SARS-CoV-2. Results: Across datasets, we observed 930,669 individuals with positive RNA for SARS-CoV-2. Of these, 35,806 (4%) were serotested within 90 days; 15% of which occurred 30%) in some datasets—limiting our ability to examine differences in serological testing by race. In datasets where race/ethnicity information was available, we observed a greater distribution of White individuals among those serotested; however, the time between RNA and serology tests appeared shorter in Black compared to White individuals. Test manufacturer data was available in half of the datasets contributing to the analysis. Conclusion: Our results inform the underlying context of serotesting during the first year of the COVID-19 pandemic and differences observed between claims and EHR data sources–a critical first step to understanding the real-world accuracy of serological tests. Incomplete reporting of race/ethnicity data and a limited ability to link test manufacturer data, lab results, and clinical data challenge the ability to assess the real-world performance of SARS-CoV-2 tests in different contexts and the overall U.S. response to current and future disease pandemics.

13 January 2025 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
AAAyad K. Ali
Ayad K. Ali
ABAidan Baglivo
Aidan Baglivo
PGPriya Govil
Priya Govil
LGLiza R. Gibbs
Liza R. Gibbs
MBMarie C. Bradley
Marie C. Bradley
EGElizabeth M Garry
Elizabeth M Garry